FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for lisdexamfetamine dimesylate from Hikma Pharmaceuticals USA Inc., resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Binge Eating Disorder

Drugs mentioned

• LISDEXAMFETAMINE DIMESYLATE (Lisdexamfetamine dimesylate)

Snippet

SUPPL AP for LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)